SEC Filing Summary: Revelation Biosciences, Inc. (REVB)
Business Context and Reporting Period
This Form 8-K, dated March 6, 2025, serves as a current report for Revelation Biosciences, Inc., a Delaware corporation headquartered in San Diego, California. The filing references the company's financial results for the three and twelve months ended December 31, 2024, which were announced via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1) but are not embedded in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It solely acts as a notification that the results for the period ended December 31, 2024, have been issued.
Guidance, Outlook, and Risks
The text does not include specific guidance, management commentary, risk factors, or contingencies. It notes that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures for the three and twelve months ended December 31, 2024.
- Verify the company's cash position and burn rate, as these are critical for a biotechnology firm but are not listed in this summary text.
- Confirm the status of the redeemable warrants (REVBW) and their exercise price of $193,200.00 per share.
- Check for any subsequent filings that may incorporate the press release information by reference.